{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+to+Severe+Atopic+Dermatitis", "query": { "condition": "Moderate to Severe Atopic Dermatitis" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 223, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Moderate+to+Severe+Atopic+Dermatitis&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T11:39:52.147Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03562377", "title": "Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Tdap vaccine", "type": "BIOLOGICAL" }, { "name": "Meningococcal vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "54 Years", "sex": "ALL", "summary": "18 Years to 54 Years" }, "enrollment_count": 215, "start_date": "2018-07-13", "completion_date": "2019-11-22", "has_results": true, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-07-24T11:39:52.147Z", "location_count": 39, "location_summary": "Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03562377" }, { "nct_id": "NCT07220577", "title": "Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "GIA632", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 34, "start_date": "2025-11-10", "completion_date": "2027-09-06", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-07-24T11:39:52.147Z", "location_count": 3, "location_summary": "Fremont, California • Rockville, Maryland • Hoboken, New Jersey", "locations": [ { "city": "Fremont", "state": "California" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Hoboken", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07220577" }, { "nct_id": "NCT06224348", "title": "A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis Atopic" ], "interventions": [ { "name": "Amlitelimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Topical corticosteroids", "type": "DRUG" }, { "name": "Topical calcineurin inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 643, "start_date": "2024-01-18", "completion_date": "2025-11-01", "has_results": false, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-07-24T11:39:52.147Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Encino", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06224348" }, { "nct_id": "NCT06407934", "title": "A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis Atopic" ], "interventions": [ { "name": "Amlitelimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1541, "start_date": "2024-05-08", "completion_date": "2027-03-17", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-07-24T11:39:52.147Z", "location_count": 82, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06407934" }, { "nct_id": "NCT03796676", "title": "JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "PF-04965842", "type": "DRUG" }, { "name": "PF04965842", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 287, "start_date": "2019-02-18", "completion_date": "2020-04-08", "has_results": true, "last_update_posted_date": "2022-04-13", "last_synced_at": "2026-07-24T11:39:52.147Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Madera, California • Mission Viejo, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Madera", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Doral", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03796676" }, { "nct_id": "NCT05469464", "title": "Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis", "Skin Diseases" ], "interventions": [ { "name": "Orismilast modified release tablets", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNION therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2022-07-11", "completion_date": "2024-02-15", "has_results": true, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-07-24T11:39:52.147Z", "location_count": 18, "location_summary": "Canoga Park, California • Fountain Valley, California • Inglewood, California + 13 more", "locations": [ { "city": "Canoga Park", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05469464" }, { "nct_id": "NCT05958407", "title": "A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis", "Atopic Hand Eczema" ], "interventions": [ { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2023-08-28", "completion_date": "2025-09-22", "has_results": false, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-07-24T11:39:52.147Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05958407" }, { "nct_id": "NCT07167758", "title": "A Study Evaluating TRIV-509 in Atopic Dermatitis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "TRIV-509", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Triveni Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 95, "start_date": "2025-08-26", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-07-24T11:39:52.147Z", "location_count": 9, "location_summary": "Fountain Valley, California • San Diego, California • Miami, Florida + 6 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "South Bend", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07167758" }, { "nct_id": "NCT04086121", "title": "A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "Spesolimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 14, "start_date": "2019-09-24", "completion_date": "2022-02-23", "has_results": true, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-07-24T11:39:52.147Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Plainfield", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04086121" }, { "nct_id": "NCT02087943", "title": "Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dermatitis, Atopic Dermatitis" ], "interventions": [ { "name": "Apremilast", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 191, "start_date": "2014-06", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2020-05-07", "last_synced_at": "2026-07-24T11:39:52.147Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02087943" } ] }